Resverlogix（RFS）株式概要後期臨床バイオテクノロジー企業であるレスバーロジックス社は、慢性疾患患者のための治療薬を開発している。 詳細RFS ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6報酬過去5年間の収益は年間27.2%増加しました。 リスク分析キャッシュランウェイが1年未満である マイナスの株主資本 German市場と比較して、過去 3 か月間の株価の変動が非常に大きい収益が 100 万ドル未満 ( $0 )+1 さらなるリスクすべてのリスクチェックを見るRFS Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.056該当なし内在価値ディスカウントEst. Revenue$PastFuture-145m95m2016201920222025202620282031Revenue US$1.0Earnings US$0.2AdvancedSet Fair ValueView all narrativesResverlogix Corp. 競合他社RespiratoriusSymbol: DB:HF00Market cap: €17.0mBiomark DiagnosticsSymbol: DB:20BMarket cap: €36.8mGenetic AnalysisSymbol: DB:8V8Market cap: €42.1m2investSymbol: DB:2INVMarket cap: €45.8m価格と性能株価の高値、安値、推移の概要Resverlogix過去の株価現在の株価CA$0.05652週高値CA$0.1652週安値CA$0.019ベータ1.041ヶ月の変化-5.93%3ヶ月変化-14.62%1年変化94.74%3年間の変化-25.50%5年間の変化-90.98%IPOからの変化-96.86%最新ニュースお知らせ • Apr 23Resverlogix Corp., Annual General Meeting, Jun 25, 2026Resverlogix Corp., Annual General Meeting, Jun 25, 2026. Location: alberta, calgary Canadaお知らせ • Nov 19Resverlogix Appoints Bradley Glass to Board of DirectorsResverlogix Corp. announced the appointment of Mr. Bradley Glass, J.D. as a member of the Company's board of directors. Mr. Glass has served as the General Counsel of Hepalink USA Inc. and its subsidiaries ("Hepalink") for the past four years. In that role, Mr. Glass is responsible for managing all of Hepalink's U.S. legal issues. Prior to joining Hepalink, Mr. Glass was in private law practice for over twenty years and advised, counseled, and represented clients all over the United States on a broad range of matters. Mr. Glass has represented and litigated numerous matters in federal, state, and local courts and administrative tribunals on a wide range of complex business and regulatory matters. Mr. Glass is a graduate of Wabash College and the Indiana University School of Law.お知らせ • Apr 23Resverlogix Corp., Annual General Meeting, Jun 30, 2025Resverlogix Corp., Annual General Meeting, Jun 30, 2025. Location: alberta, calgary CanadaNew Risk • Aug 16New major risk - Revenue and earnings growthEarnings have declined by 29% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.9m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-US$78m). Earnings have declined by 29% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (€13.8m market cap, or US$15.1m).New Risk • Aug 15New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.1m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-US$73m). Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (€11.9m market cap, or US$13.1m).New Risk • Jul 24New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.1m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Negative equity (-US$73m). Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (2.2% increase in shares outstanding). Market cap is less than US$100m (€9.25m market cap, or US$10.0m).最新情報をもっと見るRecent updatesお知らせ • Apr 23Resverlogix Corp., Annual General Meeting, Jun 25, 2026Resverlogix Corp., Annual General Meeting, Jun 25, 2026. Location: alberta, calgary Canadaお知らせ • Nov 19Resverlogix Appoints Bradley Glass to Board of DirectorsResverlogix Corp. announced the appointment of Mr. Bradley Glass, J.D. as a member of the Company's board of directors. Mr. Glass has served as the General Counsel of Hepalink USA Inc. and its subsidiaries ("Hepalink") for the past four years. In that role, Mr. Glass is responsible for managing all of Hepalink's U.S. legal issues. Prior to joining Hepalink, Mr. Glass was in private law practice for over twenty years and advised, counseled, and represented clients all over the United States on a broad range of matters. Mr. Glass has represented and litigated numerous matters in federal, state, and local courts and administrative tribunals on a wide range of complex business and regulatory matters. Mr. Glass is a graduate of Wabash College and the Indiana University School of Law.お知らせ • Apr 23Resverlogix Corp., Annual General Meeting, Jun 30, 2025Resverlogix Corp., Annual General Meeting, Jun 30, 2025. Location: alberta, calgary CanadaNew Risk • Aug 16New major risk - Revenue and earnings growthEarnings have declined by 29% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.9m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-US$78m). Earnings have declined by 29% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (€13.8m market cap, or US$15.1m).New Risk • Aug 15New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.1m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-US$73m). Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (€11.9m market cap, or US$13.1m).New Risk • Jul 24New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.1m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Negative equity (-US$73m). Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (2.2% increase in shares outstanding). Market cap is less than US$100m (€9.25m market cap, or US$10.0m).New Risk • Jul 23New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.21m (US$10.00m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.1m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-US$73m). Revenue is less than US$1m. Market cap is less than US$10m (€9.21m market cap, or US$10.00m).New Risk • Jun 07New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.25m (US$9.99m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.1m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-US$73m). Revenue is less than US$1m. Market cap is less than US$10m (€9.25m market cap, or US$9.99m).お知らせ • Apr 20Resverlogix Corp., Annual General Meeting, Jun 27, 2024Resverlogix Corp., Annual General Meeting, Jun 27, 2024.New Risk • Apr 03New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$3.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.1m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-US$74m). Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (2.5% increase in shares outstanding). Market cap is less than US$100m (€10.3m market cap, or US$11.1m).Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 7 highly experienced directors. Director Shawn Lu was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Recent Insider Transactions • Jun 22Co-Founder recently bought €68k worth of stockOn the 17th of June, Donald McCaffrey bought around 372k shares on-market at roughly €0.18 per share. This was the largest purchase by an insider in the last 3 months. Donald has been a buyer over the last 12 months, purchasing a net total of €73k worth in shares.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 8 highly experienced directors. Independent Lead Director Norma Biln was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Executive Departure • Jul 13Senior Vice President of Business & Corporate Development Kenneth Lebioda has left the companyOn the 6th of July, Kenneth Lebioda's tenure as Senior Vice President of Business & Corporate Development ended. As of March 2021, Kenneth still personally held 186.45k shares (€109k worth at the time). Kenneth is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 11.75 years.Is New 90 Day High Low • Sep 19New 90-day high: €0.58The company is up 51% from its price of €0.39 on 19 June 2020. The German market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period.株主還元RFSDE BiotechsDE 市場7D6.7%0.2%1.6%1Y94.7%-9.8%2.2%株主還元を見る業界別リターン: RFS過去 1 年間で-9.8 % の収益を上げたGerman Biotechs業界を上回りました。リターン対市場: RFS過去 1 年間で2.2 % の収益を上げたGerman市場を上回りました。価格変動Is RFS's price volatile compared to industry and market?RFS volatilityRFS Average Weekly Movement15.2%Biotechs Industry Average Movement8.4%Market Average Movement6.0%10% most volatile stocks in DE Market13.2%10% least volatile stocks in DE Market2.7%安定した株価: RFSの株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: RFSの 週次ボラティリティ は過去 1 年間で20%から15%に減少しましたが、依然としてGerman株の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/an/aDon McCaffreywww.resverlogix.comレスバーロジックス社は後期臨床バイオテクノロジー企業で、慢性疾患患者のための治療薬を開発している。同社の主力医薬品はアパベタロン（RVX-208）で、低分子の選択的ブロモドメイン・末端外阻害剤であり、心血管疾患、慢性腎臓病、2型糖尿病、低高比重リポ蛋白コレステロール、最近の急性冠症候群、COVID-19後遺症の患者を対象としている。また、Eversana Life Science Services, LLCと提携し、米国およびカナダにおけるCOVID-19治療薬アパベタロンの商業化、心血管系および肺動脈性肺高血圧症の適応症の開発、Medison Pharma Ltd.と提携している。本社はカナダのカルガリー。もっと見るResverlogix Corp. 基礎のまとめResverlogix の収益と売上を時価総額と比較するとどうか。RFS 基礎統計学時価総額€19.71m収益（TTM）-€5.33m売上高(TTM)n/a0.0xP/Sレシオ-3.7xPER（株価収益率RFS は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計RFS 損益計算書（TTM）収益US$0売上原価US$0売上総利益US$0その他の費用US$6.22m収益-US$6.22m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-0.02グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率-97.8%RFS の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/28 23:16終値2026/05/28 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Resverlogix Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Claude CamiréParadigm Capital, Inc.null nullRoth Capital Partners
お知らせ • Apr 23Resverlogix Corp., Annual General Meeting, Jun 25, 2026Resverlogix Corp., Annual General Meeting, Jun 25, 2026. Location: alberta, calgary Canada
お知らせ • Nov 19Resverlogix Appoints Bradley Glass to Board of DirectorsResverlogix Corp. announced the appointment of Mr. Bradley Glass, J.D. as a member of the Company's board of directors. Mr. Glass has served as the General Counsel of Hepalink USA Inc. and its subsidiaries ("Hepalink") for the past four years. In that role, Mr. Glass is responsible for managing all of Hepalink's U.S. legal issues. Prior to joining Hepalink, Mr. Glass was in private law practice for over twenty years and advised, counseled, and represented clients all over the United States on a broad range of matters. Mr. Glass has represented and litigated numerous matters in federal, state, and local courts and administrative tribunals on a wide range of complex business and regulatory matters. Mr. Glass is a graduate of Wabash College and the Indiana University School of Law.
お知らせ • Apr 23Resverlogix Corp., Annual General Meeting, Jun 30, 2025Resverlogix Corp., Annual General Meeting, Jun 30, 2025. Location: alberta, calgary Canada
New Risk • Aug 16New major risk - Revenue and earnings growthEarnings have declined by 29% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.9m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-US$78m). Earnings have declined by 29% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (€13.8m market cap, or US$15.1m).
New Risk • Aug 15New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.1m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-US$73m). Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (€11.9m market cap, or US$13.1m).
New Risk • Jul 24New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.1m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Negative equity (-US$73m). Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (2.2% increase in shares outstanding). Market cap is less than US$100m (€9.25m market cap, or US$10.0m).
お知らせ • Apr 23Resverlogix Corp., Annual General Meeting, Jun 25, 2026Resverlogix Corp., Annual General Meeting, Jun 25, 2026. Location: alberta, calgary Canada
お知らせ • Nov 19Resverlogix Appoints Bradley Glass to Board of DirectorsResverlogix Corp. announced the appointment of Mr. Bradley Glass, J.D. as a member of the Company's board of directors. Mr. Glass has served as the General Counsel of Hepalink USA Inc. and its subsidiaries ("Hepalink") for the past four years. In that role, Mr. Glass is responsible for managing all of Hepalink's U.S. legal issues. Prior to joining Hepalink, Mr. Glass was in private law practice for over twenty years and advised, counseled, and represented clients all over the United States on a broad range of matters. Mr. Glass has represented and litigated numerous matters in federal, state, and local courts and administrative tribunals on a wide range of complex business and regulatory matters. Mr. Glass is a graduate of Wabash College and the Indiana University School of Law.
お知らせ • Apr 23Resverlogix Corp., Annual General Meeting, Jun 30, 2025Resverlogix Corp., Annual General Meeting, Jun 30, 2025. Location: alberta, calgary Canada
New Risk • Aug 16New major risk - Revenue and earnings growthEarnings have declined by 29% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.9m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-US$78m). Earnings have declined by 29% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (€13.8m market cap, or US$15.1m).
New Risk • Aug 15New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.1m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-US$73m). Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (€11.9m market cap, or US$13.1m).
New Risk • Jul 24New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.1m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Negative equity (-US$73m). Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (2.2% increase in shares outstanding). Market cap is less than US$100m (€9.25m market cap, or US$10.0m).
New Risk • Jul 23New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.21m (US$10.00m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.1m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-US$73m). Revenue is less than US$1m. Market cap is less than US$10m (€9.21m market cap, or US$10.00m).
New Risk • Jun 07New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.25m (US$9.99m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.1m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-US$73m). Revenue is less than US$1m. Market cap is less than US$10m (€9.25m market cap, or US$9.99m).
お知らせ • Apr 20Resverlogix Corp., Annual General Meeting, Jun 27, 2024Resverlogix Corp., Annual General Meeting, Jun 27, 2024.
New Risk • Apr 03New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$3.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.1m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-US$74m). Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (2.5% increase in shares outstanding). Market cap is less than US$100m (€10.3m market cap, or US$11.1m).
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 7 highly experienced directors. Director Shawn Lu was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Recent Insider Transactions • Jun 22Co-Founder recently bought €68k worth of stockOn the 17th of June, Donald McCaffrey bought around 372k shares on-market at roughly €0.18 per share. This was the largest purchase by an insider in the last 3 months. Donald has been a buyer over the last 12 months, purchasing a net total of €73k worth in shares.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 8 highly experienced directors. Independent Lead Director Norma Biln was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Executive Departure • Jul 13Senior Vice President of Business & Corporate Development Kenneth Lebioda has left the companyOn the 6th of July, Kenneth Lebioda's tenure as Senior Vice President of Business & Corporate Development ended. As of March 2021, Kenneth still personally held 186.45k shares (€109k worth at the time). Kenneth is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 11.75 years.
Is New 90 Day High Low • Sep 19New 90-day high: €0.58The company is up 51% from its price of €0.39 on 19 June 2020. The German market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period.
